US Patent Issued to NOVOCURE on April 7 for "Compositions and methods for increasing cancer cell sensitivity to alternating electric fields" (Israeli Inventors)

ALEXANDRIA, Va., April 7 -- United States Patent no. 12,594,421, issued on April 7, was assigned to NOVOCURE GMBH (Baar, Switzerland).

"Compositions and methods for increasing cancer cell sensitivity to alternating electric fields" was invented by Tali Voloshin-Sela (Haifa, Israel), Lilach Avigdor (Haifa, Israel) and Anat Klein-Goldberg (Haifa, Israel).

According to the abstract* released by the U.S. Patent & Trademark Office: "Disclosed herein are methods for increasing sensitivity of a cancer cell to alternating electric fields by administering an AKT inhibitor, a mammalian target of rapamycin (mTOR) inhibitor, a Phosphatidylinositol 3-Kinase (PI3K) inhibitor, and/or a Glycogen synthase kinase 3Beta (GSK3Beta) inhibitor. Disclosed are m...